Overview

A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Status:
Active, not recruiting

Trial end date:
2024-03-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to compare the safety and efficacy of Tafasitamab with BEN versus RTX with BEN in adult patients with relapsed of refractory DLBCL.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

MorphoSys AG

Collaborator:

ICON Clinical Research

Treatments:

Bendamustine Hydrochloride
Rituximab